20,863 Shares in Sanofi $SNY Purchased by M Holdings Securities Inc.

M Holdings Securities Inc. purchased a new stake in Sanofi (NASDAQ:SNY) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 20,863 shares of the company’s stock, valued at approximately $906,000.

Several other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in shares of Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after acquiring an additional 1,869 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Sanofi by 107.2% during the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Sanofi by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock valued at $2,732,000 after purchasing an additional 752 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock valued at $326,000 after purchasing an additional 347 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Sanofi by 36.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock valued at $159,000 after purchasing an additional 875 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Performance

NASDAQ SNY opened at $44.82 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The stock’s fifty day moving average is $43.67 and its two-hundred day moving average is $44.80. The firm has a market capitalization of $108.66 billion, a P/E ratio of 23.47, a price-to-earnings-growth ratio of 1.37 and a beta of 0.35. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. The business had revenue of $13.36 billion during the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The firm’s revenue was up 16.0% compared to the same quarter last year. During the same period last year, the business earned $3.24 earnings per share. On average, research analysts anticipate that Sanofi will post 5.01 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley set a $49.00 target price on shares of Sanofi in a report on Wednesday, July 8th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings lowered shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $49.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.